News archive
Showing 742 results
October 2012
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
- Leeza and family share highs, lows and insights about caring for her mother with Alzheimer's disease in new video series- Ten national contest winners recognized for words of wisdom about finding… -
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
September 2012
-
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
La iniciativa busca ayudar a cerrar la brecha del diagnóstico de los hispanos a través de recursos e información en español sobre la enfermedad de Alzheimer La compañía trabajará junto a Univision… -
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
The initiative aims to help close diagnosis gap for Hispanic Americans by providing in-language information and resources focused on Alzheimer’s diseaseThe company will work with Univision to help… -
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-Tobramycin inhalation powder (TIP) recommended for management of cystic fibrosis (CF) patients six years and older with P. aeruginosa bacteria in their lungs-P. aeruginosa (Pa) is the leading cause… -
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media Release
Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
-- Approval based on efficacy and safety demonstrated in long-term study comparing 13.3 mg/24 h to 9.5 mg/24 h in declining mild to moderate Alzheimer's patients-- New higher dose of Exelon Patch… -
Media Release
Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease